{"entity":{"id":"university-of-pisa","kind":"institution","name":"University of Pisa / Azienda Ospedaliero-Universitaria Pisana","aka":["Università di Pisa","AOUP","Pisa University Hospital"],"tldr":"Italian university and hospital whose endocrinology department, under Rossella Elisei, is one of Europe's largest thyroid cancer centres and led the EXAM trial of cabozantinib.","summary":"The University of Pisa and its hospital, the Azienda Ospedaliero-Universitaria Pisana, run one of Europe's largest thyroid disease units. The Endocrinology Unit's thyroid cancer group, led by Rossella Elisei, coordinated EXAM, the phase 3 trial reported in the Journal of Clinical Oncology in 2013 in which cabozantinib lengthened progression-free survival in progressive medullary thyroid cancer, and studies the prognostic value of RET mutations and calcitonin doubling time.","asOf":"2026-09-18","links":[{"label":"Università di Pisa","url":"https://www.unipi.it"}],"tags":[],"related":[],"cancers":["medullary-thyroid-cancer","thyroid"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["rossella-elisei"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Pisa","country":"IT","lat":43.717,"lng":10.401,"institutionType":"university","website":"https://www.unipi.it","programs":["Thyroid cancer","Endocrinology","RET-driven cancers"]},"route":"/institutions/university-of-pisa/","neighbours":{"cancer":[{"id":"medullary-thyroid-cancer","kind":"cancer","name":"Medullary thyroid cancer","route":"/cancers/medullary-thyroid-cancer/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"person":[{"id":"rossella-elisei","kind":"person","name":"Rossella Elisei","route":"/people/rossella-elisei/"}]}}